INTRODUCTION
In previous reports we have described the characteristics of the immediate-type airway response to aerosolized ascaris antigen in a group of rhesus monkeys (1, 2) . The limited population of animals with persistent and and pharmacologic characteristics described have led to the suggestion that the rhesus monkey antigeninduced airway response constitutes a primate model of human asthma (2, 3) .
The qualitative changes in pulmonary function abnormalities occurring after antigen aerosol challenge are simulated by certain immunologic stimuli (anti-IgE), histamine, carbocholine, or prostaglandin F2o, (4) .
In previous studies, we found that certain agonists would mutually potentiate the action of others on an airway response. Examples are carbocholine and antigen (5) and antigen and arachidonic acid (6) , although the latter alone would not stimulate an airway response under the conditions ofthe experiments (6) . We have not found in previous studies, two aerosolized agents which produce no airway response when delivered singly but which will do so as a combination. In this study, we report that the ionophore, A23187, aerosolized simultaneously with arachidonic acid will produce an immediate-type airway response which simulates an antigen-induced response. Neither of these agents alone produced an airway response under the conditions of the experiments. Such a model of the immediate-type airway response due to nonimmunologic stimuli permits the evaluation of agents capable of blocking the airway reaction due to ionophore and arachidonic acid.
Ifthis response to nonimmunologic stimuli is a model of immediate-type bronchial hypersensitivity, it could University monkey colony under continual observation for at least 2 yr. Two types of animals were studied. These included animals characterized as having antigen-induced respiratory responses. These animals have cutaneous reactivity to ascaris antigen (4) at dilutions of 1:1,000 or greater and consistent and persistent responses to repeated ascaris antigen aerosol challenge (4 Aerosol challenge and determination of pulmonary function parameters. Animals received aerosol challenge no more frequently than every 2 wk. For an aerosol experiment, monkeys were anesthetized with pentobarbital and an endotracheal tube and an esophageal catheter were inserted. After a period of observation, the animals received a control aerosol challenge with phosphate-buffered 0.15 M NaCl, pH 7.35 (PBS). Base-line pulmonary function studies were obtained. Next the test aerosol challenge was delivered in a standard manner (7) . All challenges were with an in-line nebulizer in a Bird Mark 7 (Bird Corp., Palm Springs, Calif.) respirator with all settings controlling respirations constant for each experiment in each animal. They received 15 inhalations of challenging agent and changes in pulmonary functions subsequent to this challenge were recorded. The animals are free-breathing except during the aerosol challenge. The methodology for recording changes in pulmonary functions has been described in detail (8) . The following parameters ofrespiration were recorded: respiratory frequency (f), peak expiratory flow rate (PEFR), tidal volume (VT), airway resistance (Raw), and dynamic compliance (Cdyn). The PEFR is the maximal expiratory flow during quiet (nonforced) expirations. The endotracheal tube inserted into each animal was the largest tube possible. The resistance ofthe tubes ranged from 4 In a series (2, 6, 8, 10) , it has been established that although the absolute base-line pulmonary function levels varied between animals (8), these levels did not change significantly (>10%) in an animal that had no aerosol challenge or in an animal challenged by aerosol with PBS. Atropine did not result in more than that percentage of variation from the base-line. Because of this, the most useful system for analysis of the respiratory response was found to be the comparison of postchallenge results with each agonist and those obtained during the control period after the PBS challenge, with expression of the results as percent change from the base-line control period. The minimal criteria for positive responses in individual parameters are: f, +20%; Raw, +25%; VT, -15%; Cdyn, -20%; PEFR, -25%. These criteria represent mean+2 SD based on 25 challenges with PBS. Four out of the five parameters must meet the above criteria to be considered a positive response in an individual experiment.
RESULTS
Effect of A23187 and arachidonic acid as single aerosol agents. When increasing concentrations of A23187 (0.2, 2, 20, and 200 Ag/ml) were given by aerosol to reactive or nonreactive monkeys, no airway response occurred. Similarly, when increasing concentrations of arachidonic acid (0.1, 1.0, and 10 mg/ml) were aerosolized, no airway response in monkeys occurred. 200 ,ug/ml of A23187 and 10 mg/ml of arachidonic acid were the maximal concentrations of these agents used in subsequent aerosol experiments.
Effect of A23187 and arachidonic acid aerosolized simultaneously. When these agents were aerosolized simultaneously using 200 gg of A23187/ml and 10 mg of arachidonic acid/ml, an airway response occurred (Fig. 1A) . This airway response is qualitatively similar to an antigen-induced response with an increase in f, Raw, and a decrease in Cdyn, PEFR (1) . A further characteristic of the A23187 and arachidonic acid response was immediate onset (pulmonary function changes usually occurred at 2 min after completion of challenge). When either A23187 or arachidonic acid was given singly before the A23187-arachidonic acid challenge, no response occurred but this was followed by a response when the two agents (A) Challenge of a rhesus monkey with arachidonic acid (10 mg/ml) alone, in which no response is seen, followed by a second challenge in which a combination of arachidonic acid (10 mg/ml) and A23187 (200 ,g/ml) results in a response.
(B) Effect of 10 mg/ml ETYA on the monkey airway response to arachidonic acid (10 mg/ml) and A23187 (200 ,ug/ml). Inhibition by ETYA. Animals which had demonstrated airway responses to the combination of A23187 and arachidonic acid were pretreated by aerosol of ETYA in 40% ethanol using a concentration of 10 mg/ml. After the ETYA, the A23187 and arachidonic acid were delivered by aerosol. The results of such an experiment are shown in Fig. 2B and demonstrate inhibition of the expected response to A23187 and arachidonic acid in the airway reactive monkeys. This inhibition occurred in four successive experiments.
Inhibition by FPL 55712. The slow-reacting substance (SRS) antagonist (10 mg/ml) was given simultaneously with A23187 and arachidonic acid. The results of such an experiment are shown in Fig. 3A . In a In separate experiments FPL 55712 (10 mg/ml) was given after the A23187-arachidonic airway response. The FPL 55712 did not acutely reverse the airway response.
Inhibition by indomethacin. Indomethacin (10 mg/ml) in 50% ethanol had no effect on the pulmonary response parameters of the rhesus monkey. When indomethacin was aerosolized before the delivery of A23178 and arachidonic acid by aerosol the airway response to the latter two agents was inhibited. The results of an indomethacin inhibition experiment are shown in Fig. 3B . Similar inhibition of the A23187-arachidonic acid response was seen in six additional experiments. In dose-response studies, indomethacin completely inhibited the A23187-arachidonic response at concentrations of 10, 5, and 1 mg/ml. Using a concentration of 0.1 mg/ml there was no inhibition of the response.
Analysis of inhibition experiments. The statistical analysis of all of the inhibition experiments is shown in Fig. 4 . The results were obtained using the Student's t test for independent means (11). Using indomethacin there was statistically significant inhibition of changes in four of five pulmonary function parameters of the A23187-arachidonic acid response. Similarly ETYA inhibited four of five of the changes in pulmonary function parameters due to A23187-arachidonic acid challenge. FPL 55712 clearly inhibited only the change in frequency usually resulting from the A23187-arachidonic acid response (Fig. 4 ). An inhibiting effect on VT, Raw, and Cdyn might be suggested but is clearly not statistically significant by our method of analysis (Fig. 4) .
DISCUSSION
Under the conditions of these experiments, when the ionophore, A23187, and arachidonic acid were aerosolized simultaneously, an immediate-type airway response in rhesus monkeys occurred although neither agent alone induced such a response. Linoleic and linolenic acids did not produce the response seen with arachidonic acid. The airway response qualitatively simulated an ascaris antigen-induced response (1) and was demonstrated only in that group of monkeys which have airway responses to antigen, analogous to human antigen-induced asthma. These animals have hyperactive airways to challenge with analogous of acetylcholine (2, 3), histamine, and prostaglandin (PG) F2, (3 (17) . The formation of PGD2 from rat basophilic leukemia cells was blocked by indomethacin at a concentration which did not block SRS-A formation (18) . ETYA which blocks both the lipooxygenase and cyclooxygenase pathways of arachidonic metabolism, blocks production of SRS-A from the basophilic leukemic cells, while indomethacin (an inhibitor of the cyclooxygenase metabolic pathway of arachidonic acid) does not (14) . This has been suggested as evidence that SRS-A is formed from arachidonic acid through the lipooxygenase pathway.
The results of our studies might, in part, be related to the in vitro studies described above. Because A23187 and arachidonic acid in combination produce an airway response but not separately this suggests that the response is due to metabolites of arachidonic acid produced by cells stimulated with A23187. The inhibition of the response by ETYA would be consistent with this explanation because ETYA inhibits the known cyclooxygenase pathway and lipooxygenase pathway of'arachidonic acid. An alternative explanation for the action of ETYA in our experiments is that ETYA has been shown to inhibit mediator release from mast cells (19) .
Indomethacin aerosolized before A23187 and arachidonic acid inhibited the response to these agents. (3) but also PGD2 and PG122 produce immediate-type airway responses in rhesus monkeys. Indomethacin inhibits prostaglandin synthesis in a large variety of tissues (20) . The action of indomethacin is presumed to be an effect on the cyclooxygenase that converts arachidonic acid to prostaglandins (21, 22) . However, indomethacin may act in a variety of systems such as inhibition of phospholipase A2 (23) which results in release of arachidonic acid (24) . Because the airway response described here with A23187 required the presence ofarachidonic acid the action ofindomethacin as an inhibitor of phospholipase A2, generation of arachidonic acid is considered unlikely. The action of indomethacin may best be ascribed to inhibition of cyclooxygenase or one of the other enzyme systems that generate prostaglandins which are inhibited by indomethacin. (20) . In previous studies we have shown that indomethacin will potentiate an antigen-induced airway response (6) . In more recent unpublished dose-response studies of the potentiation of the Raw change occurred at concentrations of indomethacin of 0.1 and 0.01 mg/ml but not with a concentration of indomethacin of 0.001 mg/ml. Our doseresponse studies ofthe inhibitory effect of indomethacin showed inhibition over a wide range of doses except at the lowest dose. These divergent results between the A23187-arachidonic acid response and the antigeninduced response may indicate a difference between these two models of immediate airway response. The SRS-A antagonist, FPL 55712 showed no definitive inhibitory effect on the A23187-arachidonic acid response except for the inhibition of an effect on f (Fig. 4) . Because FPL 55712 has a very short half-life (25) , it is possible that SRS-A activity could not be blocked by the FPL 55712 under the conditions of these experiments. However, FPL55712 did not reverse the A23187-arachidonic airway response either.
The airway response to A23187 and arachidonic acid in this study occurred only in monkeys with defined airway responsiveness to antigen. This could be due to different bioaetive materials or amounts of materials produced. Alternatively, the bioactive materials produced could stimulate the hyperactive airway of these antigenreactive monkeys but not the airways of normal monkeys. Because of the known hyperresponsiveness of this group of animals to such agents as histamine and PGF2a,,, the latter explanation seems more likely.
